Neoantigen Analysis Report: Case HCC1395_TUMOR_DNA

Case Summary This analysis was performed on a human tumor DNA sample (Case ID: HCC1395) to identify potential neoantigen targets for personalized immunotherapy. Out of 191,645 total mutations analyzed, 1,648 candidates passed initial bioinformatic filters. From this pool, several high-priority neoantigens were identified based on their predicted ability to trigger an immune response.

Top Vaccine Candidates The following peptides represent the most promising candidates for vaccine development. These were selected based on their high "composite score," which combines predicted binding strength with the likelihood of the immune system recognizing them.

1. TESK1 (Peptide: YSLPRAAAL): This is the highest-ranked candidate. It results from a missense mutation (where one amino acid is swapped for another) in the TESK1 gene. It shows exceptional binding affinity to the HLA-C*16:01 allele.
2. FLNA (Peptide: SSFTVHCSK): This candidate is derived from a mutation in the FLNA gene. It is highly ranked due to its high Variant Allele Frequency (VAF ~0.99), meaning this mutation is present in nearly every tumor cell analyzed, making it a highly consistent target.

Practical Note on IC50 Scores: In this report, the IC50 score measures how much of a peptide is required to inhibit 50% of the binding to an HLA molecule. In clinical terms, lower is better. A lower IC50 (such as the 3.5 nM seen in the TESK1 candidate) indicates a very "tight" or strong bond between the neoantigen and the patient's immune cells, which is a prerequisite for a potent vaccine response.

Visual Findings

• Binding Affinity Distribution: The bar chart displays the top 20 candidates by binding strength. All top candidates fall well below the 500 nM threshold (indicated by the red dashed line), which is the standard benchmark for "strong binders." Notably, all top-ranked candidates also possess a composite score $\ge$ 0.5, designating them as high-priority targets.
• Mutation Landscape: The pie chart illustrates the nature of the mutations driving this tumor. The vast majority (88.7%) are missense mutations, which change single amino acids. A smaller portion (9.6%) are frameshift (FS) mutations, which alter the entire reading frame of the gene. This high proportion of missense mutations provides a clear pathway for peptide-based vaccine design.

Recommended Next Steps

• RNA Validation: While these candidates are identified via DNA, it is critical to confirm that these mutated sequences are actually being expressed as proteins. I recommend consulting with an RNA synthesis or transcriptomics lab to validate the expression of TESK1 and FLNA mutations.
• Vaccine Formulation: Given the high VAF and strong binding scores, these candidates are suitable for consideration in a personalized mRNA or peptide-based vaccine protocol.
• Combination Therapy: Consider evaluating these candidates in conjunction with checkpoint inhibitors (e.g., anti-PD-1) to enhance the T-cell response against these specific targets.

Limitations and Uncertainties This report is based on computational predictions (in silico). While the binding affinity and immunogenicity scores are high, these models cannot guarantee that a patient's immune system will successfully mount a response in vivo. This pipeline does not account for potential tumor microenvironment suppression or the physical accessibility of these antigens to T-cells. Clinical validation through functional assays is required before therapeutic implementation.